在实体器官移植中使用实体数据对 CYP3A5 基因型引导的塔克罗利斯剂量的成本效益分析
Kimberly M Deininger1, Heather D Anderson2, George P Patrinos3,4,5
1Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.
The pharmacogenomics journal
|May 15, 2024
概括
基因型导向的塔克罗利斯剂量可能会改善结果,但在移植后增加成本. 成本效益因器官而异,心脏和肺部移植显示出更高的潜在节约. 对于特定的患者群体需要进行进一步的研究.
科学领域:
- 药物基因组学和移植医学
- 卫生经济学和研究成果研究成果
背景情况:
- 塔克罗利木斯是移植后的关键免疫抑制剂,但其有效性受到遗传变异的影响.
- 标准护理 (SOC) 剂量的塔克罗利斯可以导致低于最佳的暴露和不良事件.
- CYP3A5基因型影响着塔克罗利斯的新陈代谢,这表明个性化剂量的潜力.
研究的目的:
- 在脏,肝脏,心脏和肺移植接受者中,评估使用CYP3A5基因型指导塔克罗利莫斯剂量与SOC的成本效益.
- 从美国医疗保健支付人的角度评估经济影响.
主要方法:
- 开发了决策树模型,以比较移植后前六个月的临床和经济结果.
- 基因型频率,医生采用,塔克罗利斯暴露 (TAC TTR-Rosendaal),临床结果和成本的输入来自文学和现实世界的数据.
- 进行了敏感性分析,以评估研究结果的可靠性.
主要成果:
- 每次避免事件的增量成本因移植类型而异:脏176,667美元,肝脏364,000美元,心脏12,982美元和肺部93,333美元.
- 用基因型导向剂量节省成本的概率为19.8% (脏),32.3% (肝脏),51.8% (心脏) 和54.1% (肺).
- 医生对基因型结果的使用和在治疗范围内达到高塔克罗利时间 (TAC TTR-Rosendaal) 是关键因素.
结论:
- 以CYP3A5基因型为指导的塔克罗利斯剂量比SOC提供了轻微的临床益处,但初始成本更高.
- 成本效益取决于器官,心脏和肺移植显示出更大的经济优势潜力.
- 建议进一步关注中间结果的经济评估,特别是对于具有高CYP3A5表达频率的人群.
相关概念视频
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...